Zinbryta (daclizumab) / Biogen, AbbVie 
Welcome,         Profile    Billing    Logout  
 160 Diseases   4 Trials   4 Trials   682 News 


123456»
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Retrospective data, Review, Journal, Immunomodulating:  Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Sep 10, 2024   
    Given the relative rarity of PMS, controlled, non-randomised studies on large samples may usefully integrate data from pivotal RCTs. Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Clinical, Retrospective data, Review, Journal:  Induction therapy in heart transplantation: A systematic review and network meta-analysis for developing evidence-based recommendations. (Pubmed Central) -  May 8, 2024   
    Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments. With low and very low certainty in the synthetized evidence, these NMAs suggest possible superiority of rATG compared to basiliximab, but do not provide compelling evidence for the routine use of these agents in HT recipients.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Two for One: Unilateral Placement of Dual Kidney Transplant (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_786;    
    With low and very low certainty in the synthetized evidence, these NMAs suggest possible superiority of rATG compared to basiliximab, but do not provide compelling evidence for the routine use of these agents in HT recipients. Donor characteristics : age 65
  • ||||||||||  Review, Journal:  Interleukin inhibitors and the associated risk of candidiasis. (Pubmed Central) -  Apr 16, 2024   
    In contrast, tocilizumab, an inhibitor of IL-6, has demonstrated an elevated risk in the context of coronavirus disease 2019 (COVID-19) treatment, as evidenced by a 6.9% prevalence of candidemia among patients using the drug...Future prospective studies need to exhaustively investigate candidiasis and its associated risk factors in patients receiving IL inhibitors. Implementing enduring surveillance methods is crucial to ensure IL inhibitors safe and efficient utilization of in clinical settings.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Review, Journal, Immunomodulating:  Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Jan 4, 2024   
    More than half of the included studies were sponsored by pharmaceutical companies and this may have influenced their results. Further studies should focus on direct comparison between active agents, with follow-up of at least three years, and assess other patient-relevant outcomes, such as quality of life and cognitive status, with particular focus on the impact of sex/gender on treatment effects.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Review, Journal, Adverse events:  Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Nov 30, 2023   
    At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, future systematic reviews should also include non-randomized studies.
  • ||||||||||  Review, Journal:  Treatment with Biologic Drugs in Pediatric Beh (Pubmed Central) -  Oct 22, 2023   
    Both group of biologic treatments appeared to be effective and have an acceptable safety profile in pediatric BD. However, controlled studies are required for analyzing indications for biologic treatments in pediatric BD.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie
    CD25-specific aptamer conjugated with cytotoxic payloads shows the potential to modulate immune-suppressive environment in tumors by depleting Tregs selectively (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1386;    
    Unlike anti-CD25 daclizumab, CD25-specific aptamer did not affect the activation of both CD4+ and CD8+ cytotoxic T cells in human PBMC...The complete regression of tumors was observed in both cases. Conclusions CD25-specific aptamer and its drug conjugate CD25-MMAE showed their potential to modulate immune-suppressive tumor microenvironment by selectively inhibiting and depleting CD25-high Treg. Moreover CD25-MMAE could be developed as an option for some types of blood cancers with the high expression of CD25.
  • ||||||||||  Entyvio (vedolizumab) / Takeda, Zinbryta (daclizumab) / Biogen, AbbVie
    Journal:  A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiology. (Pubmed Central) -  Aug 23, 2023   
    By integrating with proteomic data we identify the transcription factor FOG2 as an early regulator of platelet formation and ?-granularity. Finally, we show that colocalisation of our associations with disease risk signals can suggest aetiological cell-types-variants in IL2RA and ITGA4 respectively mirror the known effects of daclizumab in multiple sclerosis and vedolizumab in inflammatory bowel disease.
  • ||||||||||  Long-term insulin independence following allogenic islet transplant and childbirth (Indigo H) -  Jul 7, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_415;    
    5y post-IT and 7y PP with only oral DM medication support. While pregnancy in T1D and immunosuppression remains high risk, this suggests that successful childbirth post-IT can be safely achieved without significantly compromising graft function.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie
    Preclinical, Journal:  Enhanced effect of X-rays in the presence of a static magnetic field within a 3d pancreatic cancer model. (Pubmed Central) -  Dec 9, 2022   
    With limited understanding of the potential interaction phenomenon between SMF and radiation, this 3D system allows combination evaluation for a cancer in which the role of radiotherapy is still evolving. This study examined the use of a 3D model to investigate MR-guided radiotherapy in a hypoxic microenvironment, indicating that this could be a useful platform to further understanding of SMF influence on radiation.
  • ||||||||||  Novel Drugs in the Treatment of Steroid Refractory Acute Graft Versus Host Disease () -  Nov 29, 2022 - Abstract #ASH2022ASH_7880;    
    treated 62 patients with daclizumab in a phase II trial with reportef ORR of 68.80% at 44 months follow up.Groth et al...Monoclonal antibodies in particular showed good treatment outcomes with tolerable safety profile. Further studies are required to identify a valuable therapeutic option, SR-aGVHD.
  • ||||||||||  trichostatin A (VTR-297) / Vanda, Zinbryta (daclizumab) / Biogen, AbbVie
    Preclinical, Journal:  TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer's disease-relevant phenotypes in mice. (Pubmed Central) -  Nov 29, 2022   
    These results show that the acetylation of TFEB, as a novel mechanism of TFEB activation, promotes lysosome biogenesis and alleviates the pathogenesis of Alzheimer's disease. Our results also suggest that HDAC inhibition can promote lysosome biogenesis, and this may be a potential therapeutic approach for the treatment of neurodegenerative diseases and disorders related to HDAC hyperactivation.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Promacta (eltrombopag) / Novartis, Zinbryta (daclizumab) / Biogen, AbbVie
    Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_5683;    
    The different management strategies were registered and categorized as: 1) cyclosporin +/- steroids (CyA), 2) eltrombopag + CyA, 3) eltrombopag single agent, and 4) other...Over a median follow-up of 48 months (6-278), 27% of patients, younger and with higher PLT counts (Table1) were judged eligible to observation-only whilst the others received CyA (42%), CyA+eltrombopag (10%), eltrombopag alone (6%), and other treatments (15%; N=16 androgens, 8 ATG, 3 alemtuzumab, 2 daclizumab, 1 azathioprine, and 5 unknown)...This is one of the largest NSAA series ever reported highlighting that the use of CyA+/- eltrombopag leads to a significant clinical improvement with a favourable impact on survival. Occurrence of G3 gastrointestinal/liver toxicity in patients receiving combination therapy deserves attention and further studies.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical characteristics and disability progression in late-onset MS (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1404;    
    Around half of the treated LOMS (54.5%) had been exposed to high efficacy therapies (fingolimod, natalizumab, rituximab, ocrelizumab, alemtuzumab, daclizumab and HSCT) compared to almost two thirds of AOMS (66.1 %). Significant differences in clinical characteristics, treatment approaches and risk for disability progression distinguish LOMS from AOMS.
  • ||||||||||  Reevaluating Clinical Outcomes of Patients on Combination Biologics (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2143;    
    Further inquiry is required to determine if certain combinations biologics have a safer risk profile than others. Many biologics were not included in study due lack of unique J-code.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie, tabalumab (LY2127399) / Eli Lilly
    Review, Journal:  What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us? (Pubmed Central) -  Jul 23, 2022   
    mAbs that have been proven to be safe in other autoimmune conditions, will not have the same safety profile in MS due to immunopathogenetic differences in these diseases (e.g., daclizumab)...Memory B cells are central players in MS immunopathogenesis (e.g., tabalumab)...The success of trials on remyelination-promoting therapies mainly depends on the sufficient high dose of mAb, the optimal readout for 'proof of concept', time of treatment initiation, and appropriate selection of patients. Failed strategies are highly important to better understand assumed immunopathophysiological mechanisms and optimizing future trial designs.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie, Istodax (romidepsin) / Astellas, BMS
    Journal:  Deacetylation mechanism and potential reversal strategy of long QT syndrome on hERG K channel under hypoxia. (Pubmed Central) -  Jul 16, 2022   
    The inhibitors of HDAC1, HDAC2, and HDAC6 could reverse the reduction of hERG mRNA and hERG protein expression under hypoxia. In conclusion, deacetylation of hERG gene-associated histones and hERG protein might be the mechanisms for LQTS in patients with hypoxia, and the inhibition of HDAC1, HDAC2, and HDAC6 might be a promising reversal strategy for reducing hERG expression under different pathological conditions.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Journal, Adverse events, Real-world evidence:  Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study. (Pubmed Central) -  Jun 24, 2022   
    Our data revealed the new MS agents are associated with various undefined cardiovascular complications. These findings potentially instigate further studies to personalize prescribing these agents for MS based on patient's cardiovascular profile.
  • ||||||||||  Journal:  Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. (Pubmed Central) -  Apr 9, 2022   
    New advances in biologics are the biosimilar molecules, which are biological products that are highly similar to the reference product, and they include Infimab (biosimilar of infliximab), Exemptia or Adfrar (biosimilar of adalimumab), and Intacept or Etacept (biosimilar of etanercept)...Thus, biologics are the future of uveitis treatment with promising results. This article aims to summarize the current knowledge on biologics and their clinical utility in the management of NIU.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Zinbryta (daclizumab) / Biogen, AbbVie
    Clinical, Retrospective data, Review, Journal:  A Network Meta-Analysis of Induction Immunosuppression for Simultaneous Pancreas-Kidney Transplant From Randomized Clinical Trials. (Pubmed Central) -  Mar 12, 2022   
    Daclizumab with 2 doses, given before simultaneous pancreas-kidney transplant, was associated with the best rates of patient and graft survival. Despite the recent withdrawal of daclizumab, an alternative anti-interleukin 2 induction regimen (basiliximab) has demonstrated promising results in nonrandomized series, warranting that further highquality large-scale randomized clinical trials are still needed.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie
    Therapeutic targeting of hypoxia tolerance and oxygen consumption in pancreatic cancer (Section 6) -  Mar 9, 2022 - Abstract #AACR2022AACR_2917;    
    It has been shown PDAC hypoxia levels are highly heterogeneous and that patient-derived-xenografts (PDXs) of PDAC have similar histological phenotypes including hypoxia to their matching primary tumours...This is correlated with differences in their functional characteristics and genomic features. Understanding the impact of oxygen consumption and hypoxia tolerance on the individual tumour hypoxia levels sets the stage for identifying genetic drivers of tumour hypoxia and development of hypoxia-targeted therapies.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie
    Journal:  Gestational diabetes triggers postpartum cardiac hypertrophy via activation of calcineurin/NFAT signaling. (Pubmed Central) -  Jan 26, 2022   
    In contrast, the CaMKII/HDAC hypertrophy pathway was active immediately after giving birth and returned to the baseline by two months postpartum in both WT and HIP females...No such effects occurred in the WT. These results suggest that a GDM-complicated pregnancy accelerates the development of pathological cardiac remodeling likely through activation of calcineurin/NFAT signaling.